The increasing prevalence of various types of cancer around world is driving the global oncology molecular diagnostics market, says Fortune Business Insights in a report, titled “Oncology Molecular Diagnostics Market Size, Share and Global Trend By Product (Instruments, Reagents), By Cancer Type (Blood Cancer, Prostate Cancer, Colorectal Cancer, Skin Cancer, Cervical Cancer), By Technology (Polymerase Chain Reaction, Chips & Microarrays, Sequencing, Mass Spectroscopy, Transcription Mediated Amplification), By End User (Hospitals, Diagnostic Centers) and Geography Forecast till 2026.” The rising shift towards precision medicine is expected to enable the growth of the global oncology molecular diagnostics market.
Browse Complete Report:
Major Leading Players Mentioned:
- Dickinson and Company
- Hoffmann-La Roche Ltd
- Bayer AG
- Agilent Technologies
- Sysmex Corporation
- Siemens Healthcare GmbH.
Get Sample PDF:
Rapid Adoption of Advanced Diagnostics Techniques Will Boost Growth in North America
Geographically, the global oncology molecular diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle and Africa. North America is expected to dominate the global oncology molecular diagnostics market during the forecast period owing to the rapid adoption of advanced diagnostics techniques and sedentary lifestyles. According to the American Cancer Society (ACS), melanoma or skin cancer is the most common type of cancer occurring in the U.S. and is estimated that approximately 91,270. Favourable health reimbursement policies will further augment growth in the region. In Asia Pacific, the oncology molecular diagnostics market is predicted to grow at a significant rate owing to the growing geriatric population and rising research on precision medicines. The high unmet cancer needs are also expected to enable growth in Asia Pacific.
More Trending Topics From Fortune Business [email protected]